Inner Cosmos is pursuing a minimally invasive implantable neuromodulation system for depression, effectively bringing a psychiatry indication into a category more commonly associated with movement disorders or epilepsy. The company’s differentiation lies in applying digital precision-stimulation concepts to mental health, though it remains early relative to established psychiatric neuromodulation platforms.